দেশ: যুক্তরাজ্য
ভাষা: ইংরেজি
সূত্র: MHRA (Medicines & Healthcare Products Regulatory Agency)
Human papillomavirus type 6 L1 protein; Human papillomavirus type 31 L1 protein; Human papillomavirus type 58 L1 protein; Human papillomavirus type 52 L1 protein; Human papillomavirus type 11 L1 protein; Human papillomavirus type 16 L1 protein; Human papillomavirus type 18 L1 protein; Human papillomavirus type 33 L1 protein; Human papillomavirus type 45 L1 protein
Merck Sharp & Dohme Ltd
J07BM03
Human papillomavirus type 6 L1 protein; Human papillomavirus type 31 L1 protein; Human papillomavirus type 58 L1 protein; Human
Suspension for injection
Intramuscular
No Controlled Drug Status
Valid as a prescribable product
BNF:
PACKAGE LEAFLET: INFORMATION FOR THE USER GARDASIL® 9 SUSPENSION FOR INJECTION IN A PRE-FILLED SYRINGE Human Papillomavirus 9-valent Vaccine (Recombinant, adsorbed) This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects. READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU OR YOUR CHILD ARE VACCINATED BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU OR YOUR CHILD. - Keep this leaflet. You may need to read it again. - If you have any further questions, please ask your doctor, pharmacist or nurse. - If you or your child get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Gardasil 9 is and what it is used for 2. What you need to know before you or your child receive Gardasil 9 3. How Gardasil 9 is given 4. Possible side effects 5. How to store Gardasil 9 6. Contents of the pack and other information 1. WHAT GARDASIL 9 IS AND WHAT IT IS USED FOR Gardasil 9 is a vaccine for children and adolescents from 9 years of age and adults. It is given to protect against diseases caused by Human Papillomavirus (HPV) types 6, 11, 16, 18, 31, 33, 45, 52 and 58. These diseases include pre-cancerous lesions and cancers of the female genitals (cervix, vulva, and vagina), pre-cancerous lesions and cancers of the anus and genital warts in males and females. Gardasil 9 has been studied in males and females 9 to 26 years of age. Gardasil 9 protects against the HPV types that cause most cases of these diseases. Gardasil 9 is intended to prevent these diseases. The vaccine is not used to treat HPV related diseases. Gardasil 9 does not have any effect in individuals who already have a persistent infection or disease associated with any of the HPV types in the vaccine. However, in individuals who are already infected with one or more of the vaccine HPV সম্পূর্ণ নথি পড়ুন
OBJECT 1 GARDASIL 9 Summary of Product Characteristics Updated 01-Mar-2017 | Merck Sharp & Dohme Limited This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions. 1. Name of the medicinal product Gardasil® 9 suspension for injection. Gardasil® 9 suspension for injection in a pre-filled syringe. Human Papillomavirus 9-valent Vaccine (Recombinant, adsorbed) 2. Qualitative and quantitative composition 1 dose (0.5 ml) contains approximately: Human Papillomavirus 1 Type 6 L1 protein 2,3 Human Papillomavirus 1 Type 11 L1 protein 2,3 Human Papillomavirus 1 Type 16 L1 protein 2,3 Human Papillomavirus 1 Type 18 L1 protein 2,3 Human Papillomavirus 1 Type 31 L1 protein 2,3 Human Papillomavirus 1 Type 33 L1 protein 2,3 Human Papillomavirus 1 Type 45 L1 protein 2,3 Human Papillomavirus 1 Type 52 L1 protein 2,3 Human Papillomavirus 1 Type 58 L1 protein 2,3 30 micrograms 40 micrograms 60 micrograms 40 micrograms 20 micrograms 20 micrograms 20 micrograms 20 micrograms 20 micrograms 1 Human Papillomavirus = HPV. 2 L1 protein in the form of virus-like particles produced in yeast cells (_Saccharomyces cerevisiae_ CANADE 3C-5 (Strain 1895)) by recombinant DNA technology. 3 Adsorbed on amorphous aluminium hydroxyphosphate sulphate adjuvant (0.5 milligrams Al). For the full list of excipients, see section 6.1. 3. Pharmaceutical form Suspension for injection. Suspension for injection in a pre-filled syringe. Clear liquid with white precipitate. 4. Clinical particulars 4.1 Therapeutic indications Gardasil 9 is indicated for active immunisation of individuals from the age of 9 years against the following HPV diseases: • Premalignant lesions and cancers affecting the cervix, vulva, vagina and anus caused by vaccine HPV types • Genital warts (_Condyloma acuminata_) caused by specific HPV types. See sections 4.4 and 5.1 for important informa সম্পূর্ণ নথি পড়ুন